Buruli ulcer in this sub-Saharan African country for 2001–2010, including prevalence within a hospital population and clinical presentation of the cases. These data can be used to assess long-term developments in the number of cases of Buruli ulcer in this region.

In Gabon, the major focus of Buruli ulcer is the area around Lambaréné (population ≈25,000), the capital of Moyen Ogooué Province (population ≈35,000). It is located near the equator in the central African rainforest. Lambaréné lies near the confluence of 2 major rivers, Ogooué and Ngounié, and is the starting point for one of the largest river deltas in Africa. Numerous lakes are present throughout the region.

The Albert Schweitzer Hospital in Lambaréné serves the entire province. At this hospital, Buruli ulcer is diagnosed on the basis of clinical presentation. In addition, tissue samples are sent to the Prince Leopold Institute of Tropical Medicine in Belgium for PCR analysis. All cases are treated surgically, and since 2006, patients have received rifampin and streptomycin as well. Since 2007, patient information has been recorded on a BU-02 form, designed by the World Health Organization to register and report cases of Buruli ulcer (1).

We reviewed cases of Buruli ulcer at the Albert Schweitzer Hospital. We checked the hospital registry and patient records from 2001 through 2010 to identify probable cases of Buruli ulcer on the basis of clinical appearance and response to treatment. We also gathered information from BU-02 forms from 2007 through 2010.

During 2001–2010, the number of patients admitted to surgical wards because of suspected Buruli ulcer ranged from 5 to 40 per year (average 25 patients/year) (Figure). Despite moderate variability from year to year, the number of cases over the years increased ($\chi^2$ for trend, p = 0.003), which could be associated with increased awareness of the disease. The variability was not caused by changes in the number of patients hospitalized.

During 2007–2010, detailed clinical information from BU-02

---

Buruli Ulcer in Gabon, 2001–2010

To the Editor: Worldwide, Buruli ulcer is the third most common mycobacterial infection, following only tuberculosis and leprosy (1,2). It has been identified in 30 countries, including 12 African countries (1–3). For Gabon, the first report of a case consistent with Buruli ulcer was published in 1961 (4). The patient was a European woman who sought care at a hospital in Lambaréné for a painless upper arm nodule, which evolved into a plaque and then an extensive ulcer. The only other Buruli ulcer reports available for Gabon are a case report from 1968 and a case-series report from 1986 (5,6).

We reviewed cases of Buruli ulcer at the Albert Schweitzer Hospital. We checked the hospital registry and patient records from 2001 through 2010 to identify probable cases of Buruli ulcer on the basis of clinical appearance and response to treatment. We also gathered information from BU-02 forms from 2007 through 2010.

During 2001–2010, the number of patients admitted to surgical wards because of suspected Buruli ulcer ranged from 5 to 40 per year (average 25 patients/year) (Figure). Despite moderate variability from year to year, the number of cases over the years increased ($\chi^2$ for trend, p = 0.003), which could be associated with increased awareness of the disease. The variability was not caused by changes in the number of patients hospitalized.

During 2007–2010, detailed clinical information from BU-02
forms was available for 77 patients. PCR results were available for 57 patients and confirmed the diagnosis for 39. Patient ages ranged from 2 to 72 years; 40 (52%) patients were <15 years of age. The male/female ratio was 0.83. For 44 (57%) of the patients, Buruli ulcer was a new diagnosis. In addition, 56 (73%) patients had an ulcerative lesion, and 21 (37%) of these had lesions >5 cm. The lesions were located on the lower arm for 41 (53%) patients, upper arm for 28 (36%) patients, chest and/or back for 7 (9%) patients, and perineal region for 1 (1%) patient.

Depending on the type of lesion, the length of hospitalization ranged from 1 to 352 days (median 31 days). The longest hospitalization was almost 1 year; the patient was a child who had severe lesions and lived in conditions in which adequate wound care and follow-up after hospital discharge were unlikely.

In Gabon, the available data on Buruli ulcer come mainly from surgical wards in areas where prevalence is high. A national survey of hospital registration data in 2005 detected 3 cases in Ngounie Province in southern Gabon and 5 cases in Woleu-Ntem Province in northern Gabon. All cases are thought to have been acquired locally, thus establishing the existence of 2 previously unknown foci (U. Ateba Ngoa et al., unpub. data).

Buruli ulcer has a strong economic effect on the community and health facilities. For example, in 2010, management of the disease at the Albert Schweitzer Hospital cost an estimated 554–1,660 euros per person, not including drug costs (7). In 2009, African countries where Buruli ulcer is endemic, including Gabon, signed the Cotonou Declaration (8). According to this declaration, these countries have committed themselves to fight Buruli ulcer by several measures, including assessing the magnitude of the disease and conducting surveillance.

U.A.N. and A.A.A. were supported by the “Deutsch-Afrikanische Kooperationsprojekte in der Infektiologie,” grant no. KR 1150/6-1.

Ulyssé Ateba Ngoa, Grgoire K. Adzoda, Bayonne Manou Louis, Ayola Akim Adeginka, and Bertrand Lell

Author affiliations: Albert Schweitzer Hospital, Lambaréné, Gabon (U. Ateba Ngoa, G.K. Adzoda, A.A. Adeginka, B. Lell); Ministry of Health, Libreville, Gabon (B.M. Louis); University of Tübingen, Tübingen, Germany (U. Ateba Ngoa, A.A. Adeginka, B. Lell); and Leiden University Medical Center, Leiden, the Netherlands (A.A. Adeginka).

DOI: http://dx.doi.org/10.3201/eid1807.110613

References

1. Asiedu K, Raviglione MC, Scherprier R, eds. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization; 2000.
2. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3:e412. http://dx.doi.org/10.1371/journal.pntd.0000412
3. Minine-Lingoupou F, Beyam N, Zan-danga G, Manirakiza A, N’Domackrah A, Njuimo S, et al. Buruli ulcer, Central African Republic. Emerg Infect Dis. 2010;16:746–8.
4. Woringen F, Tulasne R, Trens F. Large ulceration with bacillus paratuberculeux (Mycobacterium ulcerans)? [in French]. Bull Soc Fr Dermatol Syphiligr. 1961;68:325–8.
5. Burchard GD, Bierrther M. Buruli ulcer: clinical pathological study of 23 patients in, Lambaréné, Gabon. Trop Med Parasi-tol. 1986;37:1–8.
6. Carayon A, Perleuis P, Honorat M, Blin E. Ulcères par mycobactéries en Afrique. Bull Soc Med Afr Noire Lang Fr. 1968;13:670–9.
7. Yamboune Guimony HJ. Ulcere de Buruli, cout du suivi d’un malade a l’hôpital Albert Schweitzer. Mémoire de fin de cyc-le [thesis]. Libreville (Gabon): Libreville Institut de Gestion; 2010.
8. World Health Organization. Cotonou Declaration on Buruli ulcer [cited 2010 Sep 20]. http://www.who.int/neglected_diseases/Benin_declaration_2009_eng_ok.pdf

Ebola Virus Antibodies in Fruit Bats, Ghana, West Africa

To the Editor: Fruit bats are the presumptive reservoir hosts of Ebola viruses (EBOVs) (genus *Ebolavirus*, family *Filoviridae*). When transmitted to humans and nonhuman primates, EBOVs can cause hemorrhagic fevers with high case-fatality rates. In 2008, we detected Zaire EBOV (ZEOBV) antibodies in a single migratory fruit bat (*Eidolon helvum*) from a roost in Accra, Ghana (1). This bat is common in sub-Saharan Africa and lives in large colonies, often in cities. The flight of an individual *E. helvum* bat during migration has been recorded as >2,500 km (2).

To understand whether the single seropositive *Eidolon helvum* bat was evidence of EBOV circulation in the Greater Accra Region or elsewhere in sub-Saharan Africa, we tested serum of 88 nonmigratory fruit bats from the surrounding region of Ghana. Serum samples had been collected, as previously described (3,4), during May–June 2007 from fruit bats in woodland and tropical forest habitats in southern Ghana within 180 km of Accra. Initial screening for EBOV antibodies was conducted by using ELISA with a 1:1 mixture of recombinant nucleoprotein (NP) of ZEBOV and Reston EBOV (REBOV). Proteins were expressed in an *Escherichia coli* expression vector with a polyhistadine tag (1,5). Samples with optical density (OD)